GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (ASX:ACW) » Definitions » 1-Year Sharpe Ratio

Actinogen Medical (ASX:ACW) 1-Year Sharpe Ratio : -0.67 (As of Jul. 07, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-07-07), Actinogen Medical's 1-Year Sharpe Ratio is -0.67.


Competitive Comparison of Actinogen Medical's 1-Year Sharpe Ratio

For the Biotechnology subindustry, Actinogen Medical's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinogen Medical's 1-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's 1-Year Sharpe Ratio falls into.


;
;

Actinogen Medical 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.


Actinogen Medical  (ASX:ACW) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Actinogen Medical 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinogen Medical Business Description

Traded in Other Exchanges
Address
109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.

Actinogen Medical Headlines

From GuruFocus

Accuride Corporation: Earnings Report For Q2 2014

By Black Iguana Nitish 10-13-2014

Stocks That Are Making A Good Come Back

By reports.droy reports.droy 03-10-2015